MET-097i: Sustained GLP-1 Receptor Engagement

adicionou um novo artigo Outro

2025-11-09 12:57:18 -

The development of MET-097i represents a major leap forward in treating metabolic disorders such as obesity and type 2 diabetes. Created by Metsera, this next-generation GLP-1 receptor agonist is engineered as a fully biased, ultra-long-acting peptide designed to extend therapeutic benefits while fine-tuning receptor activity. Unlike conventional GLP-1 drugs, it strategically enhances favorable...

0 Comentários 0 Compartilhamentos 769 Visualizações 0 Anterior